Novel thiazolidinedione analog reduces a negative impact on bone and mesenchymal stem cell properties in obese mice compared to classical thiazolidinediones

• Main Authors: Andrea Benova (Author), Michaela Ferencakova (Author), Kristina Bardova (Author), Jiri Funda (Author), Jan Prochazka (Author), Frantisek Spoutil (Author), Tomas Cajka (Author), Martina Dzubanova (Author), Tim Balcaen (Author), Greet Kerckhofs (Author), Wouter Willekens (Author), G. Harry van Lenthe (Author), Glenda Alquicer (Author), Alena Pecinova (Author), Tomas Mracek (Author), Olga Horakova (Author), Martin Rossmeisl (Author), Jan Kopecky (Author), Michaela Tencerova (Author)
• Format: Book
• Published: Elsevier, 2022-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Objective: The use of thiazolidinediones (TZDs) as insulin sensitizers has been shown to have side effects including increased accumulation of bone marrow adipocytes (BMAds) associated with a higher fracture risk and bone loss. A novel TZD analog MSDC-0602K with low affinity to PPARγ has been develo...